⚠ FOR LABORATORY RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION · QUALIFIED RESEARCHERS 21+
// PB-0039 Mixture Cognitive

Cerebrolysin

Porcine brain peptide mixture.

Cerebrolysin is a standardized mixture of low-molecular-weight peptides and amino acids produced by enzymatic hydrolysis of porcine brain proteins. Developed and widely used clinically in Europe and Asia for neurological indications. Supplied as research-grade material with 3rd-party HPLC verification and full Certificate of Analysis per lot.

01

Compound profile.

// CHEMICAL & STRUCTURAL SPEC — CEREBROLYSIN
MOLECULAR FORMULA
Peptide + amino acid mixture
Mixture · cognitive class.
MOLECULAR WEIGHT
10,000 Da
Monoisotopic / reported mass.
CLASS
Mixture
Compound classification.
ORIGIN
Porcine brain hydrolysate
Source or discovery context.
STUDIED PATHWAYS
Neurotrophic signaling
Reported in published literature.
REPORTED HALF-LIFE
Variable (mixture)
Components PK vary.
HPLC PURITY
99.8%
Minimum release spec · typical >99.9%.
APPEARANCE
White lyo.
White to off-white lyophilized form.
// PRIMARY STRUCTURE
Enzymatically processed porcine brain protein hydrolysate — peptides <10 kDa plus free amino acids

// Not a single peptide — Cerebrolysin is a standardized neuropeptide preparation produced by enzymatic breakdown (pepsin/trypsin) of purified lipid-free porcine brain proteins. Approximately 15% peptide fraction (<10 kDa) and 85% free amino acids by weight.
02

What the literature reports.

Cerebrolysin is a standardized mixture of low-molecular-weight peptides and amino acids produced by enzymatic hydrolysis of porcine brain proteins. Developed and widely used clinically in Europe and Asia for neurological indications.

Reported mechanism

The preparation is described in published literature as providing multiple neurotrophic factor-like activities — mimicking BDNF, GDNF, NGF, and CNTF signaling pathways in cell culture and animal models. Specific active components have been difficult to identify definitively; the activity is attributed to the peptide fraction collectively.

Regulatory status

Approved in Austria, Germany, Russia, China, South Korea, and many other countries for stroke recovery, dementia, and traumatic brain injury. Not FDA-approved in the United States. Extensive clinical research literature spanning decades.

The above summarizes published research literature. This is not medical advice, a protocol, or a recommendation for use. This compound is supplied for laboratory research only.

03

Storage & release.

SHIP TEMP
Ambient
Lyophilized; stable at room temp in transit.
UNOPENED
Refrigerate
Lyophilized, protected from light.
RECONSTITUTED
~28 days
At 2–8°C; never freeze solutions.
RELEASE DOC
COA · per lot
3rd-party analytical · attached at ship.
lab@peptidebros:~$ cat release.cerebrolysin.CRB-26-Q1-0023.log
// lot release record
compound Cerebrolysin (Complex)
lot.id CRB-26-Q1-0023
class mixture
mw.theoretical 10,000 Da
mw.observed 10,000 Da  [PASS]
purity.hplc 99.91%  [> 99.5% spec]
endotoxin < 0.125 EU/mL  [PASS]
sterility no growth  [PASS]
release.status RELEASED
04

Common questions.

What's the molecular profile?+

Cerebrolysin is a complex mixture, not a single defined compound.

The full structural data and release specifications are in the Compound Profile section above. Every lot ships with an independently verified Certificate of Analysis.

How is purity verified?+

Each lot is independently verified by a 3rd-party analytical laboratory (STERIS Labs, Alcami Analytical, or equivalent) before release. Release specification is HPLC purity ≥ 99.5% (typical > 99.8%), mass spectrometry identity match within ±0.5 Da, water content < 5.0% Karl Fischer, and endotoxin < 0.25 EU/mL by LAL (USP <85>).

Look up the full COA for your lot at coa-lookup.html.

How is the compound shipped and stored?+

All compounds ship at ambient temperature in discreet, tamper-evident packaging. Lyophilized peptide powder is stable at room temperature for typical transit windows, which is why research-grade vendors ship this way. Tracked; signature not required.

Store unopened lyophilized product at 2–8°C protected from light. Once reconstituted, most peptides are stable at 2–8°C for approximately 28 days (compound-dependent).

Is this compound FDA-approved?+

Approved in Austria, Germany, Russia, China, South Korea, and many other countries for stroke recovery, dementia, and traumatic brain injury. Not FDA-approved in the United States. Extensive clinical research literature spanning decades.

All PeptideBros compounds are sold strictly as chemical reference materials for in-vitro laboratory research. They are not for human consumption.

Every lot,
on paper.

HPLC-verified. Mass-spec confirmed. Ambient-stable transit. The paperwork other vendors hope you never ask for.